Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Duloxetine Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103421854A reveals a green enzymatic route for Duloxetine intermediates, offering high purity and reduced solvent waste for pharmaceutical supply chains.
Patent CN1891683A reveals a high-pressure Mannich route for N-monosubstituted beta-ketoamines, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN108658930A reveals a cost-effective two-step synthesis for duloxetine intermediates. Achieve high purity and scalable production with reduced environmental impact.
Patent CN102191293A reveals a novel immobilized yeast method for high-purity duloxetine intermediates, offering significant cost reduction in API manufacturing and scalable supply chain solutions.
Patent CN110964703B reveals high-efficiency ketoreductase for duloxetine intermediate. Achieve cost reduction and supply reliability in pharmaceutical manufacturing.
Patent CN1678562A details a Rh-catalyzed method for high-purity amino alcohols, offering significant cost reduction in API manufacturing and scalable supply chain solutions.
Patent CN102285961B details a cost-effective racemization method for duloxetine intermediates, enhancing yield and reducing environmental impact for pharmaceutical manufacturing.
Patent CN1842523A details a novel asymmetric hydrogenation process for enantiomerically pure beta-amino alcohols, offering significant cost reduction in API manufacturing.
Patent CN105061393B reveals a novel route for (S)-(-)-3-methylamino-1-(2-thienyl)-1-propanol, offering >99% purity and >80% yield for scalable duloxetine production.
Patent CN103214452B details a novel iron-mediated reduction route for duloxetine intermediates offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN104152506B reveals a crude enzyme system for high-purity pharmaceutical intermediates. This method offers significant supply chain and cost advantages for global buyers.
Patent CN110229796B details enzymatic synthesis for high-purity duloxetine intermediates. Offers cost reduction and supply chain reliability for pharma manufacturing.
Patent CN1694878A details advanced asymmetric transfer hydrogenation for high-purity pharmaceutical intermediates, offering scalable routes for cost-effective manufacturing.
Novel NHC-Cu catalyzed route for Duloxetine intermediate offers high yield and purity. Cost-effective manufacturing solution for pharmaceutical supply chains.
Novel Ru-catalyzed route for (S)-duloxetine intermediate offers high ee and yield without nitrogen protection, reducing manufacturing costs.